Welcome to the summer edition of European Oncology and Haematology! This issue features a wide variety of articles that illustrate the increasingly personalised, multidisciplinary approach to the management of cancer and haematological diseases.
Our expert interviews aim to provide a snapshot of topical issues in haematology and haematological malignancies. In an editorial piece, new editorial board member Daniel Kelly examines the increasing complexity of the cancer nurse’s role and emphasises the need for better recognition of cancer nursing across Europe. Our review articles highlight the scope of the field of oncology, discussing topics such as the investigation of dendritic cells in cancer therapy, PARP inhibitors in recurrent ovarian cancer, Midostaurin treatment for patients with AML in combination with standard chemotherapy and novel and emerging treatments in the treatment of elapsed/refractory disease Hodgkin lymphoma.
European Oncology and Haematology would like to take this opportunity to thank all participants on this edition. We would like to thank our contributors and reviewers for providing us with insightful and informative review articles. We are grateful to members of our editorial board for their continued involvement and advice. Thanks also go to all organisations and media partners for their ongoing support. We hope that you will find this edition an enjoyable and thought-provoking read.
Foreword – European Oncology & Haematology – Summer 2019
Welcome to the summer edition of European Oncology and Haematology. This issue features a wide variety of articles that illustrate the increasingly personalised, multidisciplinary approach to the management of cancer and haematological diseases. We begin with three expert interviews, which aim to give a snapshot of topical issues in haematology and haematological malignancies. Maria Domenica Cappellini […]
Gaucher Disease for the Haematologist
Gaucher disease is the most common of the lysosomal storage disorders.1 Although individually rare, these disorders as a group are relatively common, with an incidence of about 1 in 8,000 live births,2 and therefore represent an important health problem. Gaucher disease is characterised by an enzyme deficiency causing the deposition of glucocerebroside in cells of […]
Chimeric Antigen Receptor T-cell Therapy for Relapsed or Refractory Large B-cell Lymphoma – Latest Data from the ZUMA-1 Study
Large B-cell lymphoma includes diffuse large B-cell lymphomas, primary mediastinal B-cell lymphoma and transformed follicular lymphoma. These have historically been treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). High-dose salvage chemotherapy and autologous stem-cell transplantation (SCT) can be used in case of relapse, however, patients who fail R-CHOP or relapse following SCT have a […]
Cancer Nursing Deserves Better Recognition
Cancer is a growing problem that demands the best from all sectors of the global health workforce.1 Cancer nurses make up the largest proportion of this workforce and, as well as being responsible for direct care delivery, also aim to address the unmet needs of patients and carers, such as the management of side-effects. Nurses care […]
Technical Challenges in the Manufacture of Dendritic Cell Cancer Therapies
Therapeutic cancer vaccination is a promising strategy that aims to treat late stage disease by using the patient’s own immune system.1 The immune system has the potential to eliminate cancer cells, since cancer cells express antigens that are unique to the tumour or are over-expressed in the tumour. However, despite many years of research, the effective […]
Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors
Worldwide, ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer death in women.1 The GLOBOCAN study estimated there were 239,000 new cases in 2012 and 152,000 deaths due to this disease. There are nearly 600,000 women living within 5 years of an ovarian cancer diagnosis.1 In the EU, age-adjusted ovarian […]
Midostaurin for FLT3-mutated Acute Myeloid Leukaemia – Considerations for Optimal Use
Acute myeloid leukaemia (AML) is a complex and heterogeneous disease characterised by a multitude of molecular abnormalities. Better understanding of the mutational landscape has resulted in the development of targeted treatments in the last decade.1,2 AML is the most common myeloid leukaemia in adults; the latest age-adjusted incidence rate of AML in the United States and […]
Treatment of Hodgkin Lymphoma – New and Developing Therapies and Their Potential Role in Standard of Care
Hodgkin lymphoma is a B-cell lymphoma that predominantly affects adults between 20–40 years of age, with a second incidence peak in those 55 years of age or older.1,2 It is also the most common form of lymphoma in adolescents, occurring in nearly two-thirds of patients with lymphoma between the ages of 15–19.3 Overall, the annual incidence of […]